|
注册号: Registration number: |
ChiCTR2200064100 |
|
最近更新日期: Date of Last Refreshed on: |
2023-04-21 09:33:07 |
|
注册时间: Date of Registration: |
2022-09-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
脓毒症后认知功能与精神障碍的发病机制和临床防治研究 |
|
Public title: |
Pathogenesis and clinical prevention of cognitive function and mental disorders after sepsis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
脓毒症后认知功能与精神障碍的发病机制和临床防治研究 |
|
Scientific title: |
Pathogenesis and clinical prevention of cognitive function and mental disorders after sepsis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
宋雅琴 |
研究负责人: |
祝伟 |
|
Applicant: |
Yaqin Song |
Study leader: |
Wei Zhu |
|
申请注册联系人电话: Applicant telephone: |
+86 18772954675 |
研究负责人电话:
Study leader's |
+86 13971209138 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
18772954675@163.com |
研究负责人电子邮件: Study leader's E-mail: |
tjjzkzw512@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖北省武汉市洪山区高新大道501号 |
研究负责人通讯地址: |
湖北省武汉市洪山区高新大道501号 |
|
Applicant address: |
501 Gaoxin Avenue, Hongshan District, Wuhan, Hubei |
Study leader's address: |
501 Gaoxin Avenue, Hongshan District, Wuhan, Hubei |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
华中科技大学同济医学院附属同济医院 |
||
|
Applicant's institution: |
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology |
||
|
研究负责人所在单位: |
华中科技大学同济医学院附属同济医院 |
||
|
Affiliation of the Leader: |
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
TJ-IRB20220767 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
华中科技大学同济医学院附属同济医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-07-22 00:00:00 | ||
|
伦理委员会联系人: |
杜艾桦 |
||
|
Contact Name of the ethic committee: |
Aihua Du |
||
|
伦理委员会联系地址: |
湖北省武汉市解放大道1095号 |
||
|
Contact Address of the ethic committee: |
1095 Jiefang Avenue, Wuhan, Hubei |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 27 83663625 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
tongjihlunli@163.com |
|
研究实施负责(组长)单位: |
华中科技大学同济医学院附属同济医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖北省武汉市洪山区高新大道501号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
501 Gaoxin Avenue, Hongshan District, Wuhan, Hubei |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
湖北省重点研发计划项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Key R&D Project of Hubei Province |
||||||||||||||||||||||
|
研究疾病: |
脓毒症 |
||||||||||||||||||||||
|
Target disease: |
sepsis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
1. 基于多维度、多层次的组学数据,探索脓毒症后认知功能与精神障碍的新靶点和新机制。 2. 整合临床和组学数据,利用先进的人工智能技术构建脓毒症后认知功能与精神障碍早期预警识别和决策支持系统,实现对认知功能与精神障碍的早期识别、风险分级和决策指导,以显著提高脓毒症后认知功能与精神障碍的防治效果。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To explore new targets and mechanisms of cognitive function and mental disorders after sepsis based on multi-dimensional and multi-level omics data. 2. To integrate clinical and omics data, using the advanced artificial intelligence technology to build cognitive function after sepsis and mental disorders early warning and decision support system, realize the cognitive function and mental disorders early identification, risk classification and decision-making guidance, to improve sepsis after the control effect of the cognitive function and mental disorders. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.确诊为恶性肿瘤的患者; 2.既往存在或新发各种中枢神经系统疾病; 3.已确诊为精神相关疾病; 4.妊娠期、哺乳期患者; 5.意识障碍、听力和视力受损等无法完成量表测试; 6.研究者认定不适合的情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients diagnosed with malignant tumors; 2. Existing or new central nervous system diseases; 3. Diagnosed mental illness; 4. Patients during pregnancy and lactation; 5. Impaired consciousness, hearing and vision, etc., unable to complete the scale test; 6. Situations that the researcher deems inappropriate. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-10-01 00:00:00至 To 2024-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-09-26 00:00:00 至 To 2024-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
no |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
通过发表文章的方式共享数据,请阅读网页注册指南中的原始数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Sharing data by publishing articles. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
根据入组情况收集相关的临床数据,采用电子调查问卷和电子病例系统进行管理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The relevant clinical data were collected according to the enrollment and managed by electronic questionnaire and electronic medical record system. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |